scholarly journals Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance

2018 ◽  
Vol 74 (3) ◽  
pp. 746-753 ◽  
Author(s):  
Anna Maria Geretti ◽  
Ellen White ◽  
Chloe Orkin ◽  
Anna Tostevin ◽  
Peter Tilston ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Protease Inhibitor ◽  
Transmitted Drug Resistance ◽  
First Line ◽  
Thymidine Analogue ◽  
Virological Outcomes

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

2020 ◽  
Vol 75 (12) ◽  
pp. 3517-3524
Author(s):  
M Casadellà ◽  
J R Santos ◽  
M Noguera-Julian ◽  
R Micán-Rivera ◽  
P Domingo ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Low Frequency ◽  
Transmitted Drug Resistance ◽  
Strand Transfer ◽  
Resistance Mutations ◽  
First Line ◽  
Primary Resistance ◽  
Integrase Strand Transfer Inhibitors ◽  
Virological Outcomes ◽  
Hiv 1

Abstract Background Transmission of resistance mutations to integrase strand transfer inhibitors (INSTIs) in HIV-infected patients may compromise the efficacy of first-line antiretroviral regimens currently recommended worldwide. Continued surveillance of transmitted drug resistance (TDR) is thus warranted. Objectives We evaluated the rates and effects on virological outcomes of TDR in a 96 week prospective multicentre cohort study of ART-naive HIV-1-infected subjects initiating INSTI-based ART in Spain between April 2015 and December 2016. Methods Pre-ART plasma samples were genotyped for integrase, protease and reverse transcriptase resistance using Sanger population sequencing or MiSeq™ using a ≥ 20% mutant sensitivity cut-off. Those present at 1%–19% of the virus population were considered to be low-frequency variants. Results From a total of 214 available samples, 173 (80.8%), 210 (98.1%) and 214 (100.0%) were successfully amplified for integrase, reverse transcriptase and protease genes, respectively. Using a Sanger-like cut-off, the overall prevalence of any TDR, INSTI-, NRTI-, NNRTI- and protease inhibitor (PI)-associated mutations was 13.1%, 1.7%, 3.8%, 7.1% and 0.9%, respectively. Only three (1.7%) subjects had INSTI TDR (R263K, E138K and G163R), while minority variants with integrase TDR were detected in 9.6% of subjects. There were no virological failures during 96 weeks of follow-up in subjects harbouring TDR as majority variants. Conclusions Transmitted INSTI resistance remains rare in Spain and, to date, is not associated with virological failure to first-line INSTI-based regimens.

scholarly journals Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan

2012 ◽  
Vol 67 (5) ◽  
pp. 1254-1260 ◽  
Author(s):  
Chung-Chih Lai ◽  
Chien-Ching Hung ◽  
Mao-Yuan Chen ◽  
Hsin-Yun Sun ◽  
Ching-Lan Lu ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Treatment Response ◽  
Transmitted Drug Resistance ◽  
First Line ◽  
Impact On Treatment ◽  
Hiv 1

scholarly journals Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations

PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e90710 ◽  
Author(s):  
Susana Monge ◽  
Vicente Guillot ◽  
Marta Alvarez ◽  
Natalia Chueca ◽  
Natalia Stella ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Drugs ◽  
Transmitted Drug Resistance ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document